News

Intas, Axantia sign exclusive license and supply agreement for Ranibizumab biosimilar in Middle East

Axantia will register, hold the marketing authorisation and commercialise Ranibizumab

Intas Pharmaceuticals has signed an exclusive license and supply agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the Middle East operating through its pharmaceutical subsidiaries; Pharma International Pharmaceutical & Chemical Manufacturing Co and Med City Pharmaceutical Industries for Ranibizumab (biosimilar of Lucentis). 

THIS CAN BE YOUR ADVERTISEMENT

Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries. 

Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close